GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chengdu Kanghua Biological Products Co Ltd (SZSE:300841) » Definitions » Debt-to-Asset

Chengdu Kanghua Biological Products Co (SZSE:300841) Debt-to-Asset : 0.04 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Chengdu Kanghua Biological Products Co Debt-to-Asset?

Chengdu Kanghua Biological Products Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥161 Mil. Chengdu Kanghua Biological Products Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥0 Mil. Chengdu Kanghua Biological Products Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2025 was ¥3,884 Mil. Chengdu Kanghua Biological Products Co's debt to asset for the quarter that ended in Mar. 2025 was 0.04.


Chengdu Kanghua Biological Products Co Debt-to-Asset Historical Data

The historical data trend for Chengdu Kanghua Biological Products Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chengdu Kanghua Biological Products Co Debt-to-Asset Chart

Chengdu Kanghua Biological Products Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.03 0.05 0.05

Chengdu Kanghua Biological Products Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.04 0.06 0.05 0.04

Competitive Comparison of Chengdu Kanghua Biological Products Co's Debt-to-Asset

For the Biotechnology subindustry, Chengdu Kanghua Biological Products Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chengdu Kanghua Biological Products Co's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chengdu Kanghua Biological Products Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Chengdu Kanghua Biological Products Co's Debt-to-Asset falls into.


;
;

Chengdu Kanghua Biological Products Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Chengdu Kanghua Biological Products Co's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Chengdu Kanghua Biological Products Co's Debt-to-Asset for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chengdu Kanghua Biological Products Co  (SZSE:300841) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Chengdu Kanghua Biological Products Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Chengdu Kanghua Biological Products Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Chengdu Kanghua Biological Products Co Business Description

Traded in Other Exchanges
N/A
Address
No. 182, Beijing Road, Chengdu Economic and Technological Development Zone, Sichuan Province, Chengdu, CHN, 610100
Chengdu Kanghua Biological Products Co Ltd is engaged in research, development, production, sales and technical services of biological products for prevention, and the existing products include Group ACYW135 Meningococcal Polysaccharide Vaccine-Maikexin, Rabies Vaccine (human diploid cell) for Human Use, freeze-dried - HDCV. The company's products include ACYW135 Meningococcal Polysaccharide Vaccine; and Rabies Vaccine.
Executives
Sun Wan Feng Executives
Hou Wen Li Directors, executives
Wu Wen Nian Executives
Chen Huai Gong Executives
Li Sheng You Executives
Wang Qing Han Directors, executives
Li Xiao Wen Supervisors

Chengdu Kanghua Biological Products Co Headlines

No Headlines